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Abstract 
Background: Neuropathic pain is a chronic pain due to a disorder in the peripheral or central nervous system with 
different pathophysiological mechanisms. Current treatments are not effective. Here we compared the analgesic effect 
of nefopam, and morphine in chronic constriction injury (CCI) model of neuropathic pain. 
Methods: Male wistar rat (150-200g, n=8) were divided into 3 different groups: 1- Saline-treated CCI group, 2- Saline-
treated sham group, and 3- Drug-treated CCI groups. In CCI model of neuropathic pain, the left sciatic nerve was 
exposed and 4 loose chromic gut ligatures were placed around the nerve proximal to the trifurcation. Ketamine 
60mg/kg and xylazine 10 mg/kg were used for anesthesia. Nefopam (10, 20, 30mg/kg), and morphine (1, 3, 5mg/kg) 
were injected 30 minutes before surgery and continued daily to day 14 post-ligation. Von Frey filaments for mechanical 
allodynia and acetone test for cold allodynia were respectively used as pain behavioral tests. Experiments were 
performed on day 0 (before surgery) and days 1, 3, 5,7,10 and 14 post injury. Behavioral studies were performed in a 
quiet room between  9:00  to 11:00 AM. All experiments followed the IASP guidelines on ethical standards for 
investigation of experimental pain in animals. 
Results: Nefopam (20 and 30mg/kg) blocked mechanical and cold allodynia during the experimental period, but the 
analgesic effects of morphine (5mg/kg) lasted for 7 days. 
Conclusions: It seems that nefopam could effectively reduce pain behavior compared to morphine with reduced 
adverse effects. 
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Introduction 
Neuropathic pain can arise as a result of damage to the 
peripheral or central nervous system and includes a 
variety of conditions that differ in etiology as well as 
location. Sensory abnormalities which manifest as 
allodynia (pain evoked by normally non-noxious 
stimuli), and hyperalgesia (an increased response to a 
noxious stimuli) are routinely observed in human 
neuropathic pain conditions as well as in relevant 
animal models 
1
. Neuropathic pain affects 2 to 3% of 
the population in developed countries can be 
particularly severe and debilitating, and has a profound 
effect on quality of life 
1, 2
. Many drugs are tried to 
reduce neuropathic pain but the underlying 
mechanisms of neuropathic pain are multiple and 
complex, therefore treatment and management of this 
distressing condition are suggesting the use of more 
than one type of medication 
1
.  
Among analgesics, morphine is a widely used drug in 
the treatment of moderate to severe pain. There is 
considerable controversy for opioid analgesics to treat 
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chronic pain 
3
. Opioids were reported to be ineffective 
in some patients with neuropathic pain 
1
, whereas other  
observations  suggest that opioids are effective in 
attenuating neuropathic pain 
2, 3
. The most important 
point to consider in the use of opioids in neuropathic 
pain, is their side effects (respiratory depression, 
sedation,  tolerance  and constipation) which limit their 
application 
4
. 
Nefopam, a non opioid analgesic possesses a profile 
distinct from that of opioids or anti-inflammatory 
drugs. It does not cause tolerance, withdrawal reactions 
or physical dependence, and the potential for its abuse 
is very low. This drug has been demonstrated to induce 
a rapid and strong depression of the nociceptive reflex 
in humans, probably through a central mechanism of 
action. Furthermore, nefopam does not produce 
respiratory depression even in the post-operative period 
5
. Some unpleasant adverse effects consistent with a 
central mode of action of the drug have also been 
reported during therapeutic use and include dizziness, 
headache, nausea, vomiting and sweating. However, 
the detailed mechanisms underlying the 
pharmacological actions of nefopam remain unclear 
6
. 
The antinociceptive effect of nefopam has been shown 
in animal models of acute and chronic pain and in 
human. Nefopam reduced pain in some behavioral tests 
(the hot plate 
7
, formalin 
8
; carrageenan and incision 
induced thermal hyperalgesia tests 
9
). Moreover, many 
clinical studies have evaluated the analgesic efficacy of 
nefopam in postoperative pain 
10, 11
, and a protective 
analgesic effect  when  used as a single dose in the CCI 
model of chronic neuropathic pain 
12
. 
On this background, our study was designed to 
evaluate the antiallodynic effect of nefopam in 
comparison to morphine in chronic constriction injury 
(CCI) model of neuropathic pain in rat. 
Methods 
Animals 
Experiments were carried out on male Wistar rats (150-
200g), that were housed one rat per cage and placed 
under a 12 hour light/dark cycle in a temperature-
controlled room (22 ± 1ºC). Animals had free access to 
food and water. Rats were divided randomly into 
several experimental groups, each made-up of 8 
animals. All experiments followed the IASP guidelines 
on ethical standards for investigation of experimental 
pain in animals 
13
. The animals were allowed to 
habituate to the housing facilities for one week before 
the experiments began. Behavioral studies were 
performed in a quiet room between 9:00 to 11:00 AM. 
Efforts were made to limit distress and use the 
minimum number of animals necessary to achieve 
statistical significance. 
Surgery 
We used the CCI model of neuropathic pain 
14
. The 
surgical procedure was performed under ketamine (60 
mg/kg) and xylazine (10 mg/kg) anaesthesia. The left 
sciatic nerve was exposed and 4 loose chromic gut 
ligatures were placed around the nerve proximal to the 
trifurcation. The distance between the two adjacent 
ligatures was 1 mm. The wound was irrigated with 
saline (0.9%) and closed in two layers with 4-0 silk 
(facial plane) and surgical skin staples. In the saline-
treated sham group, rats underwent the same surgical 
procedure except for the ligation.  
Drug preparation 
Nefopam (Biocodex Laboratories, France) and 
morphine (Sigma, USA) were dissolved in saline 0.9%. 
Ketamine hydrochloride (Sigma, USA) and xylazine 
hydrochloride (Sigma, USA) were used for anesthesia. 
All drugs were injected by the intra-peritoneal (i.p.) 
route. 
Drug administration 
Animals were randomly divided into three 
experimental groups: 1- Saline-treated CCI group, 2- 
Saline-treated sham group, and 3- Drug-treated CCI 
groups. Animals received morphine (1, 3, 5 mg/kg) 
15
, 
nefopam (10, 20, 30 mg/kg) (12). Drugs were injected 
30 minutes before surgery and continued daily to day 
14 post-ligation. All behavioral tests were recorded on 
day 0 (control day) before the surgery and on days 1, 3, 
5, 7, 10, and 14 post-nerve injury. The order of pain 
testing was mechanical and cold allodynia respectively 
(the interval between each test was 30 minutes).  
Behavioral tests and experimental design 
The sciatic nerve territory (mid-plantar hind paw) was 
tested for sensitivity to noxious and innocuous stimuli 
using standard behavioural assays done sequentially at 
several intervals up to 14 days following surgery. 
Animals were acclimated to the testing chambers for 
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30 min prior to testing. Mechanical and cold allodynia 
were evaluated in the animals. 
Mechanical allodynia 
Mechanical sensitivity to non-noxious stimuli was 
measured by applying a set of calibrated nylon 
monofilaments (Stoelting, USA). The von Frey 
methodology was used to assess the sensitivity of the 
skin to tactile stimulation. Von Frey filaments are 
calibrated to have a characteristic bending force when 
pressure is applied. Each rat was placed under a 
transparent plexiglass cage on an elevated metal screen 
surface with 1 cm mesh openings. Increasing strengths 
of von Frey filaments were applied sequentially to the 
plantar surface of the left hind paw of each animal. The 
minimum paw withdrawal threshold (PWT), defined as 
the minimum gram strength eliciting two sequential 
responses with 3 min intervals between them 
(withdrawal from pressure), and was recorded for the 
left paw. The intensity of mechanical stimulation was 
increased from 2 to 60 g   in a graded manner using 
successively greater diameter filaments until the hind 
paw was withdrawn. For successive tests, the 
placement of these stimuli was varied slightly from one 
trial to the next to avoid sensitization of the hind paw 
16
. 
Cold allodynia 
The acetone test 
17
 was used to determine the reactivity 
to acetone stimulus. Rats were placed under a 
transparent plexiglass cage, as described previously, 
and an acetone bubble was formed at the end of a piece 
of small polyethylene tubing that was connected to a 
syringe; then, the bubble was lightly touched to the 
heel. The acetone was applied 5 times with an interval 
of 1 min between application, and the number of paw 
lifts from surface was the response measured. The 
response was calculated as the percent of paw 
withdrawal frequency (%PWF) using the following 
equation:  (Number of paw withdrawals/5 trials) × 100. 
 
Statistical analysis  
Parametric data were analyzed for significance using 
an analysis of variance (ANOVA) followed by a post-
hoc Tukey's test. Non-parametric data were analyzed 
using 2 related samples followed by the Wilcoxon test. 
In all cases, P<0.05 was considered significant. 
Results 
Response to mechanical allodynia (von Frey 
Filament test) 
Figure 1: In the von Frey test, all saline-treated CCI 
groups were strongly allodynic, at the fifth day post-
ligation compared to the control day (P<0.001); this 
effect was sustained until the end of the study. In the 
contrary, the saline-treated sham group did not show 
pain behavior during the period of the study, in the 
drug-treated CCI groups, nefopam reduced mechanical 
allodynia at 20 and 30 mg/kg doses, but not at the dose 
of 10 mg/kg (p<0.05) (Figure 1A); morphine (5 mg/kg) 
decreased tactile allodynia until day 7, but not at the 1 
and 3 mg/kg doses (p<0.05) (Figure 1B). 
 
 
Figure 1A: Paw withdrawal threshold in response to von Frey 
filaments before and at several time points after surgery in saline-
treated CCI group, saline-treated sham group and drug-treated CCI 
group.  Nefopam (10, 20, 30mg/kg ) was injected i.p. Results are 
expressed as the mean±SEM of 8 animals per group. Nef: Nefopam, 
Asterisks indicate a significant difference between post-surgery days 
compared with day 0 (* p<0.05, ** p<0.01, ***p<0.001). 
 
 
 
Figure 1B: Paw withdrawal threshold in response to von Frey 
filaments before and at several time points after surgery in saline-
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treated CCI group, saline-treated sham group and drug-treated CCI 
group.  Morphine (1, 3, 5mg/kg) was injected i.p. Results are 
expressed as the mean±SEM of 8 animals per group. Mor: 
Morphine. Asterisks indicate a significant difference between post-
surgery days compared with day 0 (* p<0.05, ** p<0.01, 
***p<0.001). 
 
Response to cold allodynia (Acetone test) 
Figure 2: In the acetone test, the saline-treated CCI 
group, showed a significant difference in pain behavior 
(P<0.001) at the fifth day post-injury compared to day 
0; this effect continued until the end of the study. 
However, cold allodynia was not observed in the 
saline-treated sham group. In the drug-treated CCI 
group, nefopam reduced cold allodynia at the dose of 
20 and 30 mg/kg, but not at the 10 mg/kg dose 
(p<0.05) (Figure 2A). The antiallodynic effect of 
morphine (5mg/kg) lasted for 5 days, but not at the 
dose of 1 and 3mg/kg (P<.0.01) (Figure 2B).   
 
 
 
Figure 2A: The frequency of paw withdrawal in response to acetone 
before and at several time points after   surgery in saline-treated 
CCI group, saline-treated sham group and drug-treated CCI group. 
Nefopam (10, 20, 30mg/kg) was injected i.p. Results are expressed as 
the mean±SEM of 8 animals per group. Nef: Nefopam. Asterisks 
indicate a significant difference between post-surgery days 
compared with day 0 ( p<0.05, ** p<0.01, ***p<0.001). 
 
Discussion 
In this study the analgesic effects of nefopam, and 
morphine were investigated preemptively, in a rat 
model of neuropathic pain. Pre-emptive analgesia can 
provide an effective treatment which prevents the 
establishment of pain. Based on the animal model 
studies, it was suggested that pre-emptive and early 
treatment can be more effective than treatment of 
established pain 
18
. We used CCI  model of nerve 
injury which is reported  to mimic  types of 
neuropathic pain found in human 
14
. 
 
 
 
Figure 2B: The frequency of paw withdrawal in response to acetone 
before and at several time points after   surgery in saline-treated 
CCI group, saline-treated sham group and drug-treated CCI group. 
Morphine (1, 3, 5mg/kg) was injected i.p. Results are expressed as 
the mean±SEM of 8 animals per group. Mor: Morphine. Asterisks 
indicate a significant difference between post-surgery days 
compared with day 0 (p<0.05, ** p<0.01, ***p<0.001). 
 
 
The management of neuropathic pain remains a major 
clinical challenge due to the relative absence of 
clinically effective treatments 
19
. This is in part due to 
an inadequate understanding of the mechanisms 
involved in the etiology of the disease.  
 Opioids currently represent the best option for the 
management of moderate to severe trauma induced 
perioperative, cancer pain and also they are 
increasingly used for non-cancer associated chronic 
pathological pain. Although a large number of clinical 
studies have reported that opioids, particularly 
morphine, had weak analgesic efficacy in neuropathic 
pain in humans 
20, 21
. However, prolonged 
administration of opioids is associated with significant 
problems including the development of tolerance to its 
analgesic effects, and as a result higher doses of the 
drug are required over time to elicit the same degree of 
analgesia. It was reported that repeated administration 
of morphine or fentanyl also results in increasing pain 
sensitivity, a syndrome clinically known as opioid-
induced hyperalgesia 
22, 23
. Several mechanisms have 
been proposed to explain the reduced analgesic 
efficacy of opioids in animal models of neuropathic 
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pain. These include loss of functional spinal μ-and δ-
opioid binding sites, NMDA receptor-induced 
excitation of spinal neurons, antagonism of inhibitory 
opioid actions by cholecystokinin and activation of 
descending facilitatory controls 
24, 25
. While it is 
thought that opioids modulate tactile hyperalgesia 
solely by acting at neuronal opioid receptors, chronic 
morphine administration is also known to induce a 
rapid increase in the expression of the proinflammatory 
cytokines such as TNFα, IL-1β and IL-6 in a number of 
cell types within the nervous system 
26
. These 
proinflammatory cytokines which are powerful pain 
enhancing proteins that may, in turn, suppress acute 
opioid analgesia and contribute to the apparent loss of 
opioid analgesia upon repeated opioid administration 
(‘‘tolerance’’) 
27, 28
. There are some controversies 
about relative efficacy of opiate analgesics against 
neuropathic pain in clinical and experimental 
researches 
29
. Various studies have reported reduced 
antinociceptive efficacy of morphine in animal models 
of peripheral or central nerve injury. However, 
conflicting results regarding the efficacy of opioids in 
different animal models of neuropathic pain have been 
reported. While systemic administration of morphine 
attenuates allodynia and hyperalgesia in chronic 
constriction injury and spinal nerve ligation (SNL) 
models, intrathecal morphine is apparently ineffective. 
In contrast, intrathecal morphine dose-dependently 
reversed mechanical allodynia in a rat model of central 
pain, whereas systemic morphine had little effect on 
this measure 
30
. Recently, these findings have been 
challenged by Zhao et al who reported antiallodynic 
effects of both systemic and intrathecally administered 
morphine in the spinal nerve injury (SNI), SNL and 
spinal cord injury (SCI) animal models of neuropathic 
pain. These results indicate that the efficacy of opioids 
in neuropathic pain is variable and seems to depend on 
several factors (e.g., the kind of nerve injury and the 
route of drug administration). Contradictory evidence 
about the efficacy of opioids in mechano-allodynia 
comes from studies on CCI model of neuropathic pain 
14
. The multiple mechanisms involved in neuropathic 
pain is only one explanation for the controversial 
results with opioids in treating neuropathic pain 
patients 
31
. In systemic injection, mechanical allodynia 
was reduced only when a higher concentration of 
morphine (5 mg/kg) was used. It is suggested that 
systemic morphine has limited effect on mechanical 
allodynia 
32
. The preventive efficacy of morphine has 
been investigated and evidence showed that preemptive 
use of morphine produced a slight antiallodynic effect 
in CCI model of neuropathic pain 
20
. 
In our research, lower doses of morphine (1 and 3 
mg/kg) did not reduce pain behavior (mechanical and 
cold allodynia) during the experimental period. The 
antiallodynic effect of morphine was produced only in 
high dose (5 mg/kg) which lasted for 7 days, this result 
is consistent with the above mentioned studies. It 
seems that the reduced analgesic effect of morphine 
may be due to the tolerance of its analgesic effects. 
On the other hand, preemptive administration of 
nefopam, produced a long lasting analgesic effect 
compared to morphine. The mechanism of action of 
nefopam is not precisely known, several mechanistic 
studies have suggested its inhibitory effect on the 
catecholamines and serotonin reuptake in the central 
nervous system 
33
. Placebo-controlled trials suggest 
that nefopam was more analgesic than acetaminophen 
and equianalgesic with non-steroidal anti-inflammatory 
drugs. Indeed, nefopam appeared to be more analgesic 
than proparacetamol 
34
, and equianalgesic with 
ketamine 
11
. It was reported that in CCI model of 
neuropathic pain, a single dose of nefopam, 
significantly reduced pain behavior. Moreover it was 
shown that nefopam has preventive analgesic effect 
12
. 
Acute administration of nefopam exhibited a dose 
dependent attenuation of pain behavior in hot plate and 
plantar tests 
7
. Given preemptively, nefopam may be 
effective at improving postoperative pain management 
and at reducing the risk of developing postoperative 
chronic pain, because the drug has both analgesic and 
antihyperalgesic properties 
35
. In our experiment, we 
used nefopam preemptively and in a dose dependent 
manner. Nefopam 20 and 30 mg/kg showed pain 
reducing effects. Our data are in agreement with above 
mentioned studies. However it should be noted that 
nefopam 30 mg/kg produced a slight hyperexcitability 
state lasting for 15 min after drug administration. 
Therefore we suggest that nefopam 20 mg/kg could 
reduce pain behavior with lower incidence of side 
effects. Moreover nefopam was regarded as a generally 
well tolerated drug. It does not cause tolerance, 
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withdrawal reactions or physical dependence, and the 
potential for its abuse is very low 
36
. 
Conclusion 
Our results confirm previous findings concerning the 
analgesic efficacy of systemically administered 
morphine and nefopam in animal models of 
neuropathic pain. Based on previous studies on 
morphine analgesia in neuropathic pain, we also found 
that there is controversy in morphine efficacy in 
controlling pain in CCI model of neuropathic pain in 
rats. Nefopam a non opioid drug, effectively reduced 
pain behavior. It was reported that nefopam causes less 
adverse effects than morphine. Further studies are 
needed to evaluate the exact mechanism of action of 
nefopam in neuropathic pain. 
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